Combining two existing prostate cancer therapies could extend the life of men with advanced, high-risk prostate cancer by 37% according to a study presented at the world’s largest cancer conference.
The new findings could change how doctors first approach treatment of prostate cancer.
‘These are the most powerful results I’ve seen from a prostate cancer trial’ said Nicholas James – the lead author of the abstract presented as the American Society of Clinical Oncology.
‘It’s a once in a career feeling.
This is one of the biggest reductions in death I’ve seen in any clinical trial for adult cancers’.